Search results
Added:
12 months ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Oxidative Stress Genes Predict Survival in STEMI
Added:
1 year ago
Original Research
Added:
1 year ago
ESC Congress 2024 — No difference in cardiovascular outcomes between invasive and conservative strategies in elderly NSTEMI patients.Principal Investigator, Prof Vijay Kunadian (Newcastle upon Tyne Hospitals NHS Trust, UK) join us in London to discuss the key findings from the SENIOR RITA trial (NCT03052036; Newcastle-upon-Tyne Hospitals NHS Trust).The SENIOR-RITA trial is a multicenter, open…
View more
Added:
1 year ago
In this week's episode of Parallax, host Dr Ankur Kalra engages in a thought-provoking discussion with Dr Stephen Smith, a pioneer in electrocardiography and myocardial infarction diagnosis. They delve into the groundbreaking OMI/NOMI paradigm (Occlusion MI vs Non-Occlusion MI), challenging the traditional STEMI vs non-STEMI terminology that has long been the cornerstone of acute coronary…
View more
Added:
8 months ago
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the…
View more
Added:
2 months ago
Source:
Radcliffe Cardiology
The routine use of beta-blockers following myocardial infarction (MI) in patients with a preserved ejection fraction has been a topic of clinical uncertainty. A new large-scale, individual-patient data meta-analysis from the Beta-Blocker Trialists’ Collaboration Study Group, combining five major trials, has found no significant benefit for this patient population.¹MethodologyThis meta-analysis…
View more
Added:
8 months ago
Source:
Transcatheter Academy
The long-term durability of complete revascularization in older patients with myocardial infarction (MI) and multivessel disease has been a subject of recent debate. New 3-year follow-up data from the Functional Assessment in Elderly MI Patients With Multivessel Disease (FIRE) trial show that the clinical benefits of a physiology-guided complete revascularization strategy are sustained over time…
View more
Added:
6 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
ESC HFA 25: SCD-PROTECT
Added:
12 months ago
Video